Controversies in the follow-up and management of well-differentiated thyroid cancer.

in Endocrine-Related Cancer
Authors:
M D Ringel Divisions of Endocrinology and Oncology, Ohio State University, Columbus, Ohio, USA.

Search for other papers by M D Ringel in
Current site
Google Scholar
PubMed
Close
and
P W Ladenson Divisions of Endocrinology and Oncology, Ohio State University, Columbus, Ohio, USA.

Search for other papers by P W Ladenson in
Current site
Google Scholar
PubMed
Close
Free access

Sign up for journal news

Thyroid cancer is a common malignancy with an apparent increasing incidence and a wide spectrum of clinical behavior and therapeutic responsiveness. Recent advances in diagnosis, primary treatment, and long-term monitoring have led to enhanced detection of primary and recurrent disease and improvements in therapy. Controversy still surrounds several issues: the most accurate predictive staging system and histological subclassification scheme, optimal preoperative assessment and surgical extent, appropriate use of radioiodine for remnant ablation, goal for thyrotropin-suppressive thyroid hormone therapy, best practices in immediate postoperative and long-term monitoring, and approach to the patient with thyroglobulin evidence of residual disease. In this paper, recent data related to these controversial issues are critically reviewed.

 

  • Collapse
  • Expand